medigraphic.com
ISSN 1561-2945 (Print)

2019, Number 1

<< Back Next >>

Revista Cubana de Cirugía 2019; 58 (1)

Outcome analysis of the multidisciplinary evaluation Of patients with lung cancer

García RME, Gallego EY, Ramírez RE, Cárdenas ÁL, Oliva DJA, Armas MK, Benavides MA, Chávez CM

Language: Spanish
References: 40
Page: 13-26
PDF size: 334.90 Kb.


ABSTRACT

Introduction: Lung cancer represents a great burden of disease worldwide. Patient care centralization for diagnosis and treatment adds a leap in the quality of health care.
Objective: To evaluate the results of the multidisciplinary consultation of lung cancer in the province of Camagüey.
Methods: A retrospective, analytical, observational study was conducted from November 2015 to February 2017. The study population consisted of 182 patients with lung cancer who were evaluated in the multidisciplinary consultation. The sample, which was probabilistic, was made up of 182 patients diagnosed with lung cancer, coinciding with the population. We worked with an objective population made up of all the adult patients who attended the aforementioned consultation and who were diagnosed with lung cancer in the diagnostic systematics.
Results: There was a predominance of the male sex and the age group between 60 and 69 years old. All the patients were associated with the smoking habit, and had at least one chest radiograph at the time of the first evaluation. The main symptom was coughing. More than half of the patients came before 60 days after the onset of symptoms, were diagnosed and started treatment before the month. The adenocarcinoma was the most frequent histological type, as the peripheral tumor location. The functional state was deteriorated in relation to the clinical stage and the surgical treatment was the most indicated.
Conclusions: Multidisciplinary care in patients with lung cancer has become the standard of care. The centralization of care, as well as the application of a clinical approach, optimizes the use of available technology appropriate to each particular case.


REFERENCES

  1. Mao Y, Yang D, He J, Krasna MJ. Epidemiology of Lung Cancer. Surg Oncol Clin N Am. 2016 Jul; 25(3):439-45.

  2. Didkowska J, Wojciechowska U, Manczuk M, Lobaszewski J. Lung cancer epidemiology: contemporary and future challenges worldwide. Ann Transl Med. 2016 Apr; 4(8):150.

  3. Ministerio de Salud Pública; Dirección Nacional de Estadísticas y Registros Médicos. Anuario Estadístico de Salud 2017. La Habana. (Cuba): MINSAP; 2018.

  4. Dirección provincial de salud. Estadísticas de salud 2016. Camagüey: Dirección provincial de Salud; 2016.

  5. Sansó Sobras Félix José, Alonso Galbán Patricia, Torres Vidal Rosa María. Mortalidad por cáncer en Cuba. Rev Cubana Salud Pública [Internet]. 2010 Mar [citado 2017 Mar 12];36(1):78-94. Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid= S086434662010000100009&lng=es

  6. Fernández de la Vega JF, Pérez H, Samper JA. Lung cancer diagnostic delay in a Havana hospital. MEDICC Rev. 2015 Jan;17(1):55-8.

  7. Desalu OO, Fawibe AE, Sanya EO, Ojuawo OB, Aladesanmi AO, Salami AK. Lung cancer awareness and anticipated delay before seeking medical help in the middle-belt population of Nigeria. Int J Tuberc Lung Dis. 2016 Apr; 20(4):560-6.

  8. Walton L, McNeill R, Stevens W, Murray M, Lewis C, Aitken D, et al. Patient perceptions of barriers to the early diagnosis of lung cancer and advice for health service improvement. Family Practice. 2013;30(4):436-44.

  9. Evans WK. Prognostic implications of treatment delays in the surgical resection of lung cancer. Thorac Surg Clin. 2013 May; 23(2):225-32.

  10. Coory M, Gkolia P, Yang IA, Bowman RV, Fong KM. Systematic review of multidisciplinary teams in the management of lung cancer. Lung Cancer. 2008 Apr;60(1):14-21.

  11. Ung KA, Campbell BA, Duplan D, Ball D, David S. Impact of the lung oncology multidisciplinary team meetings on the management of patients with cancer. Asia Pac J Clin Oncol. 2016 Jun;12(2):e298-304.

  12. Wright FC, De Vito C, Langer B. The Expert Panel on Multidisciplinary Cancer Conferences Should All Cases of Lung Cancer be presented at Tumor Board Conferences? 127 Standards. Multidisciplinary cancer conferences: a systematic review and development of practice standards. Eur J Cancer 2007;43:1002-10.

  13. Taplin SH, Weaver S, Chollette V, Marks LB, Jacobs A, Schiff G, et al. Teams and teamwork during a cancer diagnosis: interdependency within and between teams. J Oncol Pract. 2015 May;11(3):231-8.

  14. Ellis PM. The importance of multidisciplinary team management of patients with non-small-cell lung cancer. Curr Oncol 2012;19:S7-15.

  15. Mederos Curbelo Orestes Noel, Leal Mursulí Armando, Olivera Sandoval Osvaldo, Barrera Ortega Juan C, Romero Díaz Carlos A, Cantero Ronquillo Alexis. El cáncer de pulmón y la creación de grupos multidisciplinarios de cirugía torácica. Rev Cubana Cir [Internet]. 2004 Dic [citado 2017 Mar 09];43(3-4). Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S0034-74932004000300005&lng=es

  16. Varona LC, Rodríguez Vázquez JC. "Carcinoma broncógeno: Influencia de las demoras diagnósticas y terapéuticas en la supervivencia. Hospital “Hermanos Ameijeiras”. 2003-2009." Neumología y Cirugía de Tórax. 2011;70(2): 84-93.

  17. Riquet M, Mordant P, Henni M, Wermert D, Fabre-Guillevin E, Cazes A, et al. Should all cases of lung cancer be presented at tumor board conferences? Thoracic surgery clinics. 2013;23(2):123-8.

  18. Van Schil PE, Rami-Porta R, Asamura H. The 8(th) TNM edition for lung cancer: a critical analysis. Ann Transl Med. 2018;6(5):87.

  19. Goldstraw P, Chansky K, Crowley J, Rami-Porta R, Asamura H, Eberhardt WE, et al. The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer. J Thorac Oncol. 2016 Jan;11(1):39-51.

  20. Dresler C. The changing epidemic of lung cancer and occupational and environmental risk factors. Thorac Surg Clin. 2013 May; 23(2):113-22.

  21. Samet JM. Tobacco smoking: the leading cause of preventable disease worldwide. Thorac Surg Clin. 2013 May; 23(2):103-12.

  22. American Cancer Society. Cancer facts and figures. 2007. Atlanta, GA.: 2007.

  23. Wang L, Cao Y, Ren M, Chen A, Cui J, Sun D, et al. Sex Differences in Hazard Ratio During Drug Treatment of Non-small-cell Lung Cancer in Major Clinical Trials: A Focused Data Review and Meta-analysis. Clin Ther. 2017 Jan;39(1):34-54.

  24. Rivadeneira NA, Noymer A. "You've Come a Long Way, Baby": The Convergence in Age Patterns of Lung Cancer Mortality by Sex, United States, 1959 2013. Biodemography Soc Biol. 2017;63(1):38-53.

  25. Zhang J, Jiang S. Massive haemoptysis from a central pulmonary arterial pseudoaneurysm secondary to advanced lung cancer: successful treatment by Guglielmi detachable coil embolization. Clin Respir J. 2017 Mar;11(2):258-62.

  26. William D, Travis MD, Elizabeth Brambilla MD, Masayuki Noguchi MD. International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classifcation of Lung Adenocarcinoma. Journal of Thoracic Oncology February. 2011;6(2):244-75.

  27. Yoshizawa A, Motoi N, Riely GJ, Sima CS, Gerald WL, Kris MG, et al. Impact of proposed IASLC/ATS/ERS classification of lung adenocarcinoma: prognostic subgroups and implications for further revision of staging based on analysis of 514 stage I cases. Mod Pathol. 2011 May;24(5):653-64.

  28. Honein-AbouHaidar GN, Stuart-McEwan T, Waddell T, Salvarrey A, Smylie J, Dobrow MJ, et al. How do organizational characteristics influence teamwork and service delivery in lung cancer diagnostic assessment programmes? A mixed-methods study. BMJ Open. 2017 Feb 23;7(2).

  29. Shamji FM, Deslauriers J. Fast-tracking investigation and staging of patients with lung cancer. Thorac Surg Clin. 2013 May;23(2):187-91.

  30. Caswell G, Seymour J, Crosby V, Hussain A, Manderson C, Farnan S, et al. Lung cancer diagnosed following an emergency admission: exploring patient and carer perspectives on delay in seeking help. Support Care Cancer; 2017.

  31. Suarez-Pinera M, Belda-Sanchis J, Taus A, Sanchez-Font A, Mestre-Fusco A, Jimenez M, et al. FDG PET-CT SUVmax and IASLC/ATS/ERS histologic classification: a new profile of lung adenocarcinoma with prognostic value. Am J Nucl Med Mol Imaging. 2018;8(2):100-9.

  32. Yurdakul AS, Kocaturk C, Bayiz H, Gursoy S, Bircan A, Ozcan A, et al. Patient and physician delay in the diagnosis and treatment of non-small cell lung cancer in Turkey. Cancer Epidemiol. 2015 Apr;39(2):216-21.

  33. Dische S, Gibson D, Parmar M, Saunders MI. Time course from first symptom to treatment in patients with non-small cell lung cancer referred for radiotherapy: a report by CHART Steering Committee. Thorax 1996;51:1262-5.

  34. Billings JS, Wells FC. Delays in the diagnosis and surgical treatment of lung cancer. Thorax. 1996;51:903-6.

  35. López Encuentra A, Martín de Nicolás JL, Casado López M, De Miguel Poch E, Marrón Fernández C y Grupo Cooperativo de Carcinoma Broncogénico de SEPAR (GCCB-S). Demoras en el diagnóstico y en el tratamiento quirúrgico del carcinoma broncogénico. Arch Bronconeumol. 1998;34:123-6.

  36. O'Mahony S, Nathan S, Mohajer R, Bonomi P, Batus M, Fidler MJ, et al. Survival Prediction in Ambulatory Patients With Stage III/IV Non-Small Cell Lung Cancer Using the Palliative Performance Scale, ECOG, and Lung Cancer Symptom Scale. Am J Hosp Palliat Care. 2016 May;33(4):374-80.

  37. Díaz Toledo Manuel, Cayón Escobar Isis, Crespo Díaz Tatiana T, Fernández Norma Lucrecia, Valladares Carmen Rosas. Quimioterapia en cáncer de pulmón avanzado en pacientes mayores de 60 años de edad del Hospital Benéfico-Jurídico (2008-2011). Rev haban cienc méd [Internet]. 2014 Abr [citado 2017 Mar 17];13(2):227-37. Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S1729-19X2014000200008&lng=es

  38. Cardenal F, Palmero R. Treatment of resectable stage IIIA non-small cell lung cancer. J Thorac Dis. 2017 Jan;9(1):13-5.

  39. Pless M, Stupp R, Ris HB, Stahel RA, Weder W, Thierstein S, et al. Induction chemoradiation in stage IIIA/N2 non-small-cell lung cancer: a phase 3 randomised trial. Lancet. 2015 Sep 12;386(9998):1049-56.

  40. Fernández Ruiz Diana, Cuevas Pérez Olga. CIMAvax-EGF®: vacuna terapéutica contra el cáncer de pulmón de células no pequeñas en estadios avanzados. Rev Finlay [Internet]. 2017 [citado 2018 Jul 02];7(1):3-4. Disponible en: http://scielo.sld.cu/scielo.php?script=sci_ arttext&pid=S2221-24342017000100002&lng=es




2020     |     www.medigraphic.com